Model based scheduling of CML treatments

基于模型的 CML 治疗安排

• 批准号: 328102314
• 负责人: Professor Dr.-Ing. Carsten Conradi
• 金额: --
• 依托单位: Studiengang Life Science Engineering
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2016
• 资助国家: 德国
• 起止时间: 2015-12-31 至 2018-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/328102314?language=en
• 关键词: Model; based; scheduling; CML; treatments

Chronic myeloic leukemia is a chronic disease where blood cells reproduce uncontrollable and do not grow into fully functional cells. Treatment with tyrosin kinase inhibitors (TKI) often leads to a remission that, in some cases, persists after termination of treatment. The conditions leading to such a sustained remission are presently unknown. We have developed two dynamic models describing TKI treatment. Both models reproduce the qualitative dynamics of TKI treatment equally well and are therefore a-priori equally plausible. However, only one of the models predicts a sustained remission after termination of treatment. Hence, only if patient data is compatible with this model and not the other termination of treatment should be considered. For this conclusion to hold both models have to be validated mathematically and experimentally. Mathematical validation is one goal of this proposal, preparation of a Sachmittelantrag for experimental validation and computation of optimized treatment plans the other.

慢性粒细胞白血病是一种慢性疾病，血细胞繁殖不受控制，不能生长成功能完全的细胞。使用酪氨酸激酶抑制剂(TKI)治疗通常会导致缓解，在某些情况下，这种缓解在终止治疗后仍会持续。导致这种持续缓解的条件目前尚不清楚。我们开发了两个描述TKI治疗的动态模型。这两个模型都很好地再现了TKI治疗的质量动态，因此先验上同样可信。然而，只有一个模型预测在终止治疗后持续缓解。因此，只有当患者数据与该模型兼容，而不是其他终止治疗时，才应考虑。要让这一结论成立，两个模型都必须得到数学和实验的验证。数学验证是这项建议的一个目标，准备用于实验验证的Sachmittelantrag，以及计算优化的治疗方案。